Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

Rheinbreitbach/Bonn (ots) - Jennewein Biotechnologie GmbH agreed to join forces
with Chr. Hansen Holding A/S, a leading bioscience company based in
Hoersholm/Denmark, to lead the global market for human milk oligosaccharides
(HMOs). Chr. Hansen entered into an agreement to acquire all shares in Jennewein
Biotechnologie, the innovation and market leader in this high-growth market.
Chr. Hansen plans to invest more than 200 million Euros until 2025 in new
production assets so as to meet the increasing demand for HMOs.

HMOs are complex carbohydrate structures found in human breast milk. HMOs are
used today as functional food ingredients primarily in infant nutrition and
medical nutrition. The functional health benefits of HMOs such as prebiotic
effects, reducing infection risk as well as supporting cognitive development are
also expected to be of high interest in further food markets. Jennewein
Biotechnologie has been the first to commercially produce HMOs by fermentation
and commercialize these functional carbohydrates in key markets. Jennewein
Biotechnologie has build an unrivaled IP portfolio with more than 200 patents
granted, a global customer base, a comprehensive product portfolio and strong
product pipeline over the past 15 years.

The founders and CEOs of Jennewein Biotechnologie, Dr. Stefan Jennewein and Dr.
Klaus Jennewein point out: "This partnership will further strengthen the
position of Jennewein Biotechnologie in this highly attractive growth market.
Chr. Hansen and Jennewein Biotechnologie are a perfect fit with regards to
culture, production technology, as well as product portfolio."

"I am truly excited that we have reached an agreement to acquire Jennewein .The
fast-growing HMO market is a new area that we have been following with strong
interest for some years. In truth we are making a long-term investment and
commitment to HMOs, which I am convinced will bring long-term value creation to
our shareholders. HMOs also fit perfectly with our purpose to "Grow a better
world naturally", as these are some of nature's most intricate nutritional
components" says Mauricio Graber, CEO of Chr. Hansen.

"With Chr. Hansen as the new owner, Jennewein Biotechnologie is ideally
positioned for future growth and expansion. As a partner to Jennewein from the
very beginning and long-time investor we are proud to have been part in this
success story" states Dr. Erik Hoppe, CEO of Bioventure and Lead Investor of
Jennewein Biotechnologie.

Dr. Stefan Jennewein will take the role of Chief Science and Technology Advisor
and Dr. Klaus Jennewein will retire from the company.

UBS acted as financial adviser and Hogan Lovells as legal adviser to Jennewein